Locations:
SearchDr. Aaron Gerds argues for more balance in safety reporting
When referring to early-phase trial results, researchers often conclude that a therapy was safe and well-tolerated. But what does this statement really mean? In his latest Editor’s Corner column in ASH Clinical News. Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News and Deputy Director for Research at Cleveland Clinic Cancer Center, recently delved into this thought-provoking topic, arguing the benefits of presenting research findings instead of including conclusive statements that leave room for interpretation. Read more here.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients